First Light Diagnostics

First Light Diagnostics is a biotechnology company dedicated to developing rapid diagnostic tests for infectious disease pathogens, especially those linked to hospital-associated infections. Their mission is to reduce the time needed to obtain antimicrobial susceptibility test (AST) results, allowing clinicians to make quicker, life-saving treatment decisions. The company aims to deliver these results in hours instead of days, enhancing patient outcomes and addressing the challenge of multidrug-resistant pathogens. The core technology of First Light Diagnostics is the MultiPath® platform, a benchtop analyzer that enables rapid, sensitive, and accurate detection of pathogens and their antimicrobial susceptibility. This platform provides timely data for clinicians at the onset of infection, aiding in optimal antibiotic selection. The company also offers the SensiTox® B. anthracis Toxin Test, which has received FDA clearance for the early diagnosis of inhalation anthrax, a significant biodefense concern. Their primary customers include healthcare providers and clinicians who need fast diagnostic results to inform treatment decisions for patients facing serious infections.

• Employees 19
• Founded 2008
• Annual Revenue $7500000
• Total Funding $24829230